Efficacy of sirolimus in an infant with Kasabach-Merritt phenomenon

Pediatr Int. 2018 Sep;60(9):887-889. doi: 10.1111/ped.13630. Epub 2018 Aug 8.

Authors

Chisa Kumagai^{1

2}, Michio Ozeki¹, Akifumi Nozawa¹, Hiromi Kakuda³, Toshiyuki Fukao¹

Affiliations

¹ Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido, Japan.
² Department of Pediatrics, Chuno Public Welfare Hospital, Seki, Gifu, Japan.
³ Department of Hematology/Oncology, Chiba Children's Hospital, Chiba, Japan.

PMID: 30088308
DOI: 10.1111/ped.13630

No abstract available

Keywords: adverse effect; infant; infection; mammalian target of rapamycin inhibitor; vascular neoplasm.

Publication types

Case Reports

MeSH terms

Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Infant
Kasabach-Merritt Syndrome / drug therapy*
Kasabach-Merritt Syndrome / etiology
Magnetic Resonance Imaging
Male
Sirolimus / adverse effects
Sirolimus / therapeutic use*
Vascular Neoplasms / complications*
Vascular Neoplasms / drug therapy

Substances

Immunosuppressive Agents
Sirolimus